Real-World Evidence Under Consideration For Use In Interchangeable Biosimilars Applications

 
• By Derrick Gingery
Questions to be answered
Labeling, promotional and other draft interchangeability guidances are required to be issued during BsUFA III. • Source: Alamy

More from Biosimilars

More from Biosimilars & Generics